[HTML][HTML] KRAS inhibitors–yes but what next? Direct targeting of KRAS–vaccines, adoptive T cell therapy and beyond

M Nagasaka, B Potugari, A Nguyen, A Sukari… - Cancer Treatment …, 2021 - Elsevier
Kirsten rat sarcoma viral oncogene homolog (KRAS) is a proto-oncogene of the RAS-MAPK
pathway. KRAS mutations are present in a variety of malignancies including lung, colorectal …

Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment

M Tarannum, JL Vivero-Escoto - Advanced Drug Delivery Reviews, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to its
aggressiveness and the challenges for early diagnosis and treatment. Recently …

[HTML][HTML] A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance

J Zhou, N Lyu, Q Wang, M Yang, ET Kimchi, K Cheng… - Cancer letters, 2023 - Elsevier
Abstract Tumor-associated macrophages (TAMs), as a major and essential component of
tumor microenvironment (TME), play a critical role in orchestrating pancreatic cancer (PaC) …

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

Z Zhang, H Zhang, X Liao, H Tsai - Frontiers in Cell and …, 2023 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

EA Chapeau, L Sansregret, GG Galli, P Chène… - Nature Cancer, 2024 - nature.com
The YAP–TEAD protein–protein interaction mediates YAP oncogenic functions downstream
of the Hippo pathway. To date, available YAP–TEAD pharmacologic agents bind into the …

[HTML][HTML] Lipid nanomaterials-based RNA therapy and cancer treatment

X Zhang, L Hai, Y Gao, G Yu, Y Sun - Acta Pharmaceutica Sinica B, 2023 - Elsevier
We summarize the most important advances in RNA delivery and nanomedicine. We
describe lipid nanoparticle-based RNA therapeutics and the impacts on the development of …

Drug delivery strategies for the treatment of pancreatic cancer

O Olajubutu, OD Ogundipe, A Adebayo, SK Adesina - Pharmaceutics, 2023 - mdpi.com
Pancreatic cancer is fast becoming a global menace and it is projected to be the second
leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which …

Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD)

Y Yang, L Cao, Z Guo, H Gu, K Zhang, Z Qiu - Experimental Cell Research, 2022 - Elsevier
Aberrant ubiquitin-proteasome system (UPS) contributes to tumorigeneisis or drug
resistance of Pancreatic Adenocarcinoma (PAAD). Previous studies have implicated the …

Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges

S Mundla, R Malla, MP Adem, JB Foote… - Seminars in Cancer …, 2023 - Elsevier
Obesity is a prominent health issue worldwide and directly impacts pancreatic health, with
obese individuals exhibiting a significant risk for increasing pancreatic ductal …

[HTML][HTML] The ethyl acetate extract of Vernonia amygdalina leaf ameliorates gemcitabine effect against migration and invasion of PANC-1 cells via down-regulation the …

PAZ Hasibuan, JM Keliat, MF Lubis… - Saudi Pharmaceutical …, 2024 - Elsevier
Individuals diagnosed with cancer often turn to the use of herbal remedies with the intention
of treating and ameliorating the condition, impeding the progression of metastasis …